Medicare Enrolled
Dr. Yaman Suleiman, MD
Hematology · Winter Park, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Suleiman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Suleiman? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Suleiman
Dr. Yaman Suleiman is a hematology in Winter Park, FL, with 15 years in practice. Based on federal Medicare data, Dr. Suleiman performed 176,790 Medicare services across 3,413 unique beneficiaries.
Between the years covered by Open Payments, Dr. Suleiman received a total of $7,358 from 64 pharmaceutical and/or device companies across 350 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Suleiman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice▲ Top 28% volume in FL$ $7,358 industry payments
Medicare Practice Summary
Medicare Utilization ↗176,790
Medicare services
Top 28% in FL for hematology
3,413
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,786 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 42,240 | $24 | $72 |
| Iron infusion (Feraheme) | 38,760 | $0 | $4 |
| Iron sucrose injection (Venofer) | 22,900 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 13,000 | $43 | $137 |
| Epoetin alfa injection (Procrit) for anemia | 10,710 | $6 | $23 |
| Denosumab injection (Prolia/Xgeva) | 10,260 | $18 | $51 |
| Anti-nausea injection (aprepitant) | 10,140 | $1 | $5 |
| Filgrastim injection (Zarxio) for white blood cells | 7,380 | $0 | $2 |
| Immune globulin infusion (Gammagard) | 4,044 | $36 | $108 |
| Dexamethasone injection (steroid) | 3,121 | $0 | $3 |
| Complete blood count (CBC) with differential | 2,241 | $8 | $29 |
| Blood draw (venipuncture) | 2,197 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,450 | $1 | $28 |
| Office visit, established patient (30-39 min) | 1,097 | $95 | $339 |
| Drug injection, under skin or into muscle | 1,046 | $10 | $69 |
| Injection, leucovorin calcium, per 50 mg | 826 | $3 | $12 |
| Injection of additional new drug or substance into vein | 807 | $12 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 522 | $97 | $378 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 512 | $1 | $6 |
| Anti-nausea injection (ondansetron/Zofran) | 448 | $0 | $9 |
| Injection, fluorouracil, 500 mg | 399 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 262 | $48 | $189 |
| Office visit, established patient (20-29 min) | 257 | $64 | $239 |
| Injection, carboplatin, 50 mg | 235 | $2 | $41 |
| Injection, zoledronic acid, 1 mg | 218 | $7 | $69 |
| Red blood count automated, with additional calculations | 216 | $5 | $20 |
| Injection, diphenhydramine hcl, up to 50 mg | 189 | $1 | $3 |
| Administration of chemotherapy into vein, each additional hour | 153 | $22 | $79 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 129 | $16 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 121 | $21 | $84 |
| Administration of additional new drug or substance into vein, 1 hour or less | 102 | $48 | $178 |
| Automated urinalysis | 90 | $2 | $8 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 86 | $24 | $89 |
| Administration of additional new drug or substance into vein using push technique | 86 | $42 | $170 |
| Hospital follow-up visit, moderate complexity | 59 | $63 | $197 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 57 | $126 | $637 |
| Infusion into a vein for hydration, each additional hour | 53 | $10 | $42 |
| Office visit, established patient, complex (40-54 min) | 50 | $138 | $474 |
| New patient office visit (45-59 min) | 43 | $125 | $453 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 42 | $3 | $11 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 42 | $1 | $7 |
| Infusion, normal saline solution , 1000 cc | 37 | $2 | $7 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $55 | $206 |
| New patient office visit, complex (60-74 min) | 33 | $173 | $585 |
| Injection of drug or substance into vein | 32 | $28 | $156 |
| Infusion into a vein for hydration, 31-60 minutes | 29 | $24 | $156 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $13 | $59 |
| Initial hospital admission, high complexity | 12 | $137 | $556 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
24.6% high complexity
71.7% medium
3.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,358
Total received (2018-2024)
Avg $1,051/year across 7 years
Top 50% in FL for hematology
64
Companies
350
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,714 (77.7%)
Other
Charitable contributions, space rental, and other categories
$1,407 (19.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$237 (3.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,119
2023$1,704
2022$1,429
2021$1,028
2020$236
2019$853
2018$990
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,731
Celgene Corporation
$520
E.R. Squibb & Sons, L.L.C.
$494
Genentech USA, Inc.
$321
PFIZER INC.
$286
AstraZeneca Pharmaceuticals LP
$278
Merck Sharp & Dohme LLC
$247
Daiichi Sankyo Inc.
$215
Gilead Sciences, Inc.
$212
Amgen Inc.
$207
Bayer Healthcare Pharmaceuticals Inc.
$190
NOVARTIS PHARMACEUTICALS CORPORATION
$167
Janssen Biotech, Inc.
$152
Seagen Inc.
$151
GENZYME CORPORATION
$144
Kite Pharma, Inc.
$137
Pharmacyclics LLC, An AbbVie Company
$108
United Therapeutics Corporation
$100
Lilly USA, LLC
$97
JAZZ PHARMACEUTICALS INC.
$92
EMD Serono, Inc.
$79
Astellas Pharma US Inc
$79
BeiGene USA, Inc.
$74
Incyte Corporation
$73
Bayer HealthCare Pharmaceuticals Inc.
$68
Myovant Sciences Inc.
$66
GlaxoSmithKline, LLC.
$57
Ipsen Biopharmaceuticals, Inc
$56
Agios Pharmaceuticals, Inc.
$52
MorphoSys, US Inc.
$45
ARRAY BIOPHARMA INC
$44
Karyopharm Therapeutics Inc.
$44
SOBI, INC
$43
Puma Biotechnology, Inc.
$43
AMAG Pharmaceuticals, Inc.
$39
Pharmacyclics LLC, an AbbVie Company
$38
Regeneron Healthcare Solutions, Inc.
$37
TerSera Therapeutics LLC
$36
Merck Sharp & Dohme Corporation
$36
Stemline Therapeutics Inc.
$35
CSL Behring
$35
Exelixis Inc.
$34
Alexion Pharmaceuticals, Inc.
$32
Rigel Pharmaceuticals, Inc.
$30
ABBVIE INC.
$27
TAIHO ONCOLOGY, INC.
$25
Eisai Inc.
$21
SERVIER PHARMACEUTICALS LLC
$21
EISAI INC.
$19
Servier Pharmaceuticals LLC
$18
Mirati Therapeutics, Inc.
$18
CTI BioPharma Corp.
$18
Dendreon Pharmaceuticals LLC
$18
Deciphera Pharmaceuticals Inc.
$18
Boehringer Ingelheim Pharmaceuticals, Inc.
$16
ADC Therapeutics America, Inc.
$14
PUMA BIOTECHNOLOGY, INC.
$14
SpringWorks Therapeutics, Inc.
$14
G1 Therapeutics, Inc.
$13
Verastem, Inc.
$13
Lexicon Pharmaceuticals, Inc.
$12
Adaptive Biotechnologies Corporation
$12
R-Pharm US LLC
$12
Aurobindo Pharma USA, Inc.
$11
Top 3 companies account for 37.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · Afstyla · Alecensa · Aliqopa · Avastin · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · Enhertu · FERAHEME · Folotyn · GAZYVA · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · Imbruvica · Ixempra · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MVASI · MYLOTARG · NERLYNX · Nerlynx · Nplate · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PROMACTA · PROVENGE · Padcev · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · Stivarga · TAGRISSO · TASIGNA · TIBSOVO · Tavalisse · Tibsovo · Trodelvy · ULTOMIRIS · UNITUXIN · VARUBI · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · Vanflyta · Vonjo · XALKORI · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (78%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $4 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
18
Per 100K population
3.8
County median income
$83,030
Nearest hospital
ADVENTHEALTH ORLANDO
4.7 mi
4.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Suleiman is a mixed practice specialist, with above-average Medicare volume (top 28% in FL), and low-engagement industry engagement, with 15 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Suleiman experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Suleiman performed 42,240 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Suleiman receive payments from pharmaceutical companies?
Yes. Dr. Suleiman received a total of $7,358 from 64 companies across 350 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Suleiman's costs compare to other hematologys in Winter Park?
Dr. Suleiman's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Suleiman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Winter Park
Browse hematologys in Winter Park ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology